Notice: 函数 WP_Styles::add 的调用方法不正确。 The style with the handle "storefront-woocommerce-style" was enqueued with dependencies that are not registered: storefront-style. 请查阅调试 WordPress来获取更多信息。 (这个消息是在 6.9.1 版本添加的。) in /wordpress/wp-includes/functions.php on line 6260

KB-1087

Iladatuzumab

Home » Iladatuzumab

Background of Iladatuzumab

CD79B is a cell-surface antigen expressed on mature B cells but absent on plasma cells. A majority of mature malignancies of B-cell origin, including non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia, express CD79B and demonstrate rapid internalization of anti-CD79B antibodies. Iladatuzumab (MCDS0593A) is a humanized IgG1 monoclonal antibody against human CD79B. Iladatuzumab can be used to synthesize antibody-drug conjugates (ADC) Iladatuzumab vedotin, which has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research.

Specifications

Catalog Number:
KB-1087
Antibody Name:
Iladatuzumab
Isotype:
Human IgG1,kappa
FC Muations:
WT
Target:
CD79b
Species Reactivity:
Human
Host Cell Line:
EXPI CHO
Purification Method:
Affinity purified
Concentration:
>2 mg/mL
Formulation:
50 mM sodium citrate,150mM NaCl,pH5.5
Purity:
>95% by SDS-PAGE and SEC-HPLC
Validation:
FACS
Endotoxin Level:
<0.2 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Storage:
It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

  1. Alex F Herrera, et al. Anti-CD79B Antibody-Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study. Clin Cancer Res. 2022 Apr 1;28(7):1294-1301.
  2. Louise Conilh, et al. Payload diversification: a key step in the development of antibody-drug conjugates. J Hematol Oncol. 2023 Jan 17;16(1):3.